Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCI-779 (Torisel) in Relapsed or Refractory Multiple Myeloma
NCT00079456Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2004
- Primary completion
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temsirolimus in multiple myeloma (MM), sponsored by National Cancer Institute. Primary endpoint: Overall Response Rate up to 5 years. Started Feb 2004; status: completed.
02
Drugs
temsirolimus
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00079456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00079456.